Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: prospective cohort study
- PMID: 24594868
- PMCID: PMC3942564
- DOI: 10.1136/bmj.g1219
Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: prospective cohort study
Abstract
Objectives: To determine whether the receipt of chemotherapy among terminally ill cancer patients months before death was associated with patients' subsequent intensive medical care and place of death.
Design: Secondary analysis of a prospective, multi-institution, longitudinal study of patients with advanced cancer.
Setting: Eight outpatient oncology clinics in the United States.
Participants: 386 adult patients with metastatic cancers refractory to at least one chemotherapy regimen, whom physicians identified as terminally ill at study enrollment and who subsequently died.
Primary outcomes: intensive medical care (cardiopulmonary resuscitation, mechanical ventilation, or both) in the last week of life and patients' place of death (for example, intensive care unit).
Secondary outcomes: survival, late hospice referrals (≤ 1 week before death), and dying in preferred place of death.
Results: 216 (56%) of 386 terminally ill cancer patients were receiving palliative chemotherapy at study enrollment, a median of 4.0 months before death. After propensity score weighted adjustment, use of chemotherapy at enrollment was associated with higher rates of cardiopulmonary resuscitation, mechanical ventilation, or both in the last week of life (14% v 2%; adjusted risk difference 10.5%, 95% confidence interval 5.0% to 15.5%) and late hospice referrals (54% v 37%; 13.6%, 3.6% to 23.6%) but no difference in survival (hazard ratio 1.11, 95% confidence interval 0.90 to 1.38). Patients receiving palliative chemotherapy were more likely to die in an intensive care unit (11% v 2%; adjusted risk difference 6.1%, 1.1% to 11.1%) and less likely to die at home (47% v 66%; -10.8%, -1.0% to -20.6%), compared with those who were not. Patients receiving palliative chemotherapy were also less likely to die in their preferred place, compared with those who were not (65% v 80%; adjusted risk difference -9.4%, -0.8% to -18.1%).
Conclusions: The use of chemotherapy in terminally ill cancer patients in the last months of life was associated with an increased risk of undergoing cardiopulmonary resuscitation, mechanical ventilation or both and of dying in an intensive care unit. Future research should determine the mechanisms by which palliative chemotherapy affects end of life outcomes and patients' attainment of their goals.
Conflict of interest statement
Competing interests: All authors have completed the ICJME uniform disclosure form at
Comment in
-
Chemotherapy near the end of life.BMJ. 2014 Mar 4;348:g1529. doi: 10.1136/bmj.g1529. BMJ. 2014. PMID: 24598123 No abstract available.
-
Optimising end of life care requires an individualised approach.BMJ. 2014 Mar 25;348:g2312. doi: 10.1136/bmj.g2312. BMJ. 2014. PMID: 24667297 No abstract available.
-
[Palliative chemotherapy: no effects in end-of-life care? - The ultimate objective is to respect the patient's wishes].Dtsch Med Wochenschr. 2014 Apr;139(15):766. doi: 10.1055/s-0033-1353897. Epub 2014 Apr 1. Dtsch Med Wochenschr. 2014. PMID: 24691688 German. No abstract available.
Similar articles
-
Association between palliative care and healthcare outcomes among adults with terminal non-cancer illness: population based matched cohort study.BMJ. 2020 Jul 6;370:m2257. doi: 10.1136/bmj.m2257. BMJ. 2020. PMID: 32631907 Free PMC article.
-
Social and clinical determinants of preferences and their achievement at the end of life: prospective cohort study of older adults receiving palliative care in three countries.BMC Geriatr. 2017 Nov 23;17(1):271. doi: 10.1186/s12877-017-0648-4. BMC Geriatr. 2017. PMID: 29169346 Free PMC article.
-
Family Perspectives on Aggressive Cancer Care Near the End of Life.JAMA. 2016 Jan 19;315(3):284-92. doi: 10.1001/jama.2015.18604. JAMA. 2016. PMID: 26784776 Free PMC article.
-
Where the dying live: a systematic review of determinants of place of end-of-life cancer care.Oncol Nurs Forum. 2009 Jan;36(1):69-77. doi: 10.1188/09.ONF.69-77. Oncol Nurs Forum. 2009. PMID: 19136340 Review.
-
Understanding patterns and factors associated with place of death in patients with end-stage kidney disease: A retrospective cohort study.Palliat Med. 2017 Mar;31(3):283-288. doi: 10.1177/0269216316655747. Epub 2016 Aug 19. Palliat Med. 2017. PMID: 27495813 Free PMC article. Review.
Cited by
-
Treatment Classification by Intent in Oncology-The Need for Meaningful Definitions: Curative, Palliative and Potentially Life-Prolonging.J Pers Med. 2024 Aug 31;14(9):932. doi: 10.3390/jpm14090932. J Pers Med. 2024. PMID: 39338185 Free PMC article.
-
Anticancer therapy at end-of-life: A retrospective cohort study.Acta Oncol. 2024 May 8;63:313-321. doi: 10.2340/1651-226X.2024.22139. Acta Oncol. 2024. PMID: 38716486 Free PMC article.
-
Optimising oncology drug expenditure in Ireland.Ir J Med Sci. 2024 Aug;193(4):1735-1747. doi: 10.1007/s11845-024-03672-y. Epub 2024 Apr 3. Ir J Med Sci. 2024. PMID: 38568369 Free PMC article. Review.
-
Preferences of bereaved family members on communication with physicians when discontinuing anticancer treatment: referring to the concept of nudges.Jpn J Clin Oncol. 2024 Jul 7;54(7):787-796. doi: 10.1093/jjco/hyae038. Jpn J Clin Oncol. 2024. PMID: 38553776 Free PMC article.
-
Prevalence of aggressive care among patients with cancer near the end of life: a systematic review and meta-analysis.EClinicalMedicine. 2024 Mar 21;71:102561. doi: 10.1016/j.eclinm.2024.102561. eCollection 2024 May. EClinicalMedicine. 2024. PMID: 38549585 Free PMC article.
References
-
- Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O, Ash AS. Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med 2003;138:639-43. - PubMed
-
- Braga S. Why do our patients get chemotherapy until the end of life? Ann Oncol 2011;22:2345-8. - PubMed
-
- Schnipper LE, Smith TJ, Raghavan D, Blayney DW, Ganz PA, Mulvey TM, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol 2012;30:1715-24. - PubMed
-
- Anders CK, Peppercorn J. Treating in the dark: unanswered questions on costs and benefits of late line therapy for metastatic breast cancer. Cancer Invest 2009;27:13-6. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical